early posttransplant period | |
delayed allograft function (n, %) | 14 (29.2) |
plasma creatinine at discharge (μmol/l) | 141 [106–177] |
eGFRa at discharge (ml/min/1.73 m2) | 43 [30–61] |
lowest thrombocyte count (109/L) | 101 [79–132] |
time to lowest thrombocyte count (d) | 2 [1–3] |
long-term follow-up | |
follow-up (yrs.) | 3.3 [1.5–5.6] |
all-cause allograft loss (n, %) | 14 (29.2) |
time to allograft loss (yrs.) | 2.1 [0.4–2.9] |
death-censored allograft loss (n, %) | 9 (18.8) |
plasma creatinine* (μmol/l) | 124 [106–150] |
eGFRa * (ml/min/1.73 m2) | 47 [39–65] |
BPARb (n, %) | 12 (25) |
TCMR (n, %) | 2 (4) |
ABMR (n, %) | 10 (21) |
urinary tract infections/patient/year (n) | 0.7 [0.4–2.4] |
viral infections (CMV, EBV)c (n, %) | 7 (15) |
PVANd (n, %) | 1 (2.1) |
prediabetes / PTDMe ** (n, %) | 16 (38.1) / 13 (31.0) |